Evidence map›Paper›PMID 35265825›Full record

ArticleMaterials today. Bio2022

Bone mineral: A trojan horse for bone cancers. Efficient mitochondria targeted delivery and tumor eradication with nano hydroxyapatite containing doxorubicin.

Yang Liu, Aftab Nadeem, Sujeesh Sebastian, Martin A Olsson, Sun N Wai, Emelie Styring, Jacob Engellau, Hanna Isaksson, Magnus Tägil, Lars Lidgren and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Research progress of nanomaterial drug delivery in tumor targeted therapy.Frontiers in bioengineering and biotechnology · 2023
    Review
  14. In vitro and in vivo Evaluation of Folic Acid Modified DOX-LoadedInternational journal of nanomedicine · 2023
    Article
  15. LongitudinalFrontiers in bioengineering and biotechnology · 2022
    Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yang LiuDepartment of Clinical Sciences Lund, Orthopedics, The Faculty of Medicine, Lund University, Lund, Sweden.
Aftab NadeemDepartment of Molecular Biology and the Laboratory for Molecular Infection Medicine, Sweden (MIMS), Umeå Centre for Microbial Research (UCMR), Umeå University, Umeå, Sweden.
Sujeesh SebastianDepartment of Clinical Sciences Lund, Orthopedics, The Faculty of Medicine, Lund University, Lund, Sweden.
Martin A OlssonDepartment of Theoretical Chemistry, Chemical Centre, Lund University, Lund, Sweden.
Sun N WaiDepartment of Molecular Biology and the Laboratory for Molecular Infection Medicine, Sweden (MIMS), Umeå Centre for Microbial Research (UCMR), Umeå University, Umeå, Sweden.
Emelie StyringDepartment of Clinical Sciences Lund, Orthopedics, The Faculty of Medicine, Lund University, Lund, Sweden.
Jacob EngellauMedical Radiation Physics, Lund University, Lund, Sweden.
Hanna IsakssonDepartment of Clinical Sciences Lund, Orthopedics, The Faculty of Medicine, Lund University, Lund, Sweden.
Magnus TägilDepartment of Clinical Sciences Lund, Orthopedics, The Faculty of Medicine, Lund University, Lund, Sweden.
Lars LidgrenDepartment of Clinical Sciences Lund, Orthopedics, The Faculty of Medicine, Lund University, Lund, Sweden.
Deepak Bushan RainaDepartment of Clinical Sciences Lund, Orthopedics, The Faculty of Medicine, Lund University, Lund, Sweden.
Lund University · SEUmeå University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Efficient systemic pharmacological treatment of solid tumors is hampered by inadequate tumor concentration of cytostatics necessitating development of smart local drug delivery systems. To overcome this, we demonstrate that doxorubicin (DOX), a cornerstone drug used for osteosarcoma treatment, shows reversible accretion to hydroxyapatite (HA) of both nano (nHA) and micro (mHA) size. nHA particles functionalized with DOX get engulfed in the lysosome of osteosarcoma cells where the acidic microenvironment causes a disruption of the binding between DOX and HA. The released DOX then accumulates in the mitochondria causing cell starvation, reduced migration and apoptosis. The HA+DOX delivery system was also tested in-vivo on osteosarcoma bearing mice. Locally delivered DOX via the HA particles had a stronger tumor eradication effect compared to the controls as seen by PET-CT and immunohistochemical staining of proliferation and apoptosis markers. These results indicate that in addition to systemic chemotherapy, an adjuvant nHA could be used as a carrier for intracellular delivery of DOX for prevention of tumor recurrence after surgical resection in an osteosarcoma. Furthermore, we demonstrate that nHA particles are pivotal in this approach but a combination of nHA with mHA could increase the safety associated with particulate nanomaterials while maintaining similar therapeutic potential.

Indexed as

DoxorubicinDrug deliveryNano and micro hydroxyapatiteOsteosarcomaSolid tumor

Identifiers

PMID35265825
PMCPMC8898975
OpenAlexW4214685309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.